Kasen S, Cohen P, Skodol A E, First M B, Johnson J G, Brook J S, Oldham J M
Department of Psychiatry, Columbia University, New York, NY, USA.
Acta Psychiatr Scand. 2007 Jan;115(1):56-65. doi: 10.1111/j.1600-0447.2006.00842.x.
The impact of comorbid personality disorder (PD) on subsequent treatment and psychotropic drug use was examined in a representative sample of over 700 individuals.
Axis I disorders and PD were assessed by self- and mother-report at mean ages 13 and 22 years, and by self-report at mean age 33. Mothers reported treatment use by participants before mean age 33; participants reported treatment and psychotropic drug use at mean age 33.
Individuals with multiple axis I disorders without PD, axis I disorder-PD comorbidity, and single disorders were compared simultaneously to individuals not diagnosed. Overall, odds of subsequent and past year treatment or psychotropic drug use or both were highest when PD co-occurred with a mood, an anxiety, a disruptive, or a substance use disorder.
Co-occurring personality pathology may contribute to elevated mental health service use, including use of psychotropic drugs, among young adults in the community.
在一个700多人的代表性样本中，研究共病性人格障碍（PD）对后续治疗及精神药物使用的影响。
通过自我报告和母亲报告评估13岁和22岁时的轴I障碍及PD，并通过自我报告评估33岁时的情况。母亲报告参与者在33岁之前的治疗使用情况；参与者报告33岁时的治疗及精神药物使用情况。
将患有多种无PD的轴I障碍、轴I障碍与PD共病以及单一障碍的个体与未被诊断的个体同时进行比较。总体而言，当PD与情绪、焦虑、破坏性行为或物质使用障碍同时出现时，后续及过去一年接受治疗或使用精神药物或两者兼有的几率最高。
共病性人格病理学可能导致社区中年轻人心理健康服务使用增加，包括精神药物的使用。
